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Acknowledgment of the gut microbiome as a vital asset to health has led to multiple 
studies attempting to elucidate its mechanisms of action. During the first year of life, 
many factors can cause fluctuation in the developing gut microbiome. Host genetics, 
maternal health status, mode of delivery, gestational age, feeding regime, and perinatal 
antibiotic usage, are known factors which can influence the development of the infant 
gut microbiome. Thus, the microbiome of vaginally born, exclusively breastfed infants 
at term, with no previous exposure to antibiotics, either directly or indirectly from the 
mother, is to be considered the “gold standard.” Moreover, the use of prebiotics as an 
aid for the development of a healthy gut microbiome is equally as important in main-
taining gut homeostasis. Breastmilk, a natural prebiotic source, provides optimal active 
ingredients for the growth of beneficial microbial species. However, early life disorders 
such as necrotising enterocolitis, childhood obesity, and even autism have been associ-
ated with an altered/disturbed gut microbiome. Subsequently, microbial therapies have 
been introduced, in addition to suitable prebiotic ingredients, which when administered, 
may aid in the prevention of a microbial disturbance in the gastrointestinal tract. The aim 
of this mini-review is to highlight the beneficial effects of different probiotic and prebiotic 
treatments in early life, with particular emphasis on the different conditions which nega-
tively impact microbial colonisation at birth.
Keywords: probiotics, prebiotics, gut microbiota, infant, health
inTRODUCTiOn
From birth through to the initial stages of weaning, intestinal microbial composition has a 
significant impact on infant gut health. Recent advances in culture-independent sequencing 
technologies has allowed for the identification of key microbial species involved in the initial 
colonization process, including those facultative anaerobes such as Streptococcus, Staphylococcus, 
and Enterobacter spp. (1, 2). Mode of delivery and feeding regime are two important factors which 
influence microbial colonization at birth (Figure 1). Host genetics may also impact development 
Abbreviations: GI, gastrointestinal; FT, full term; PT, preterm; VLBW, very low birth weight; GOS, galacto-oligosaccharides; 
FOS, fructo-oligosaccharides; SCFAs, short chain fatty acids; NEC, necrotizing enterocolitis; MS, metabolic syndrome; HFD, 
high-fat diet; ASD, autism spectrum disorder; MIA, maternal immune activation; NGPs, next generation probiotics; LBPs, live 
biotherapeutic products.
FigURe 1 | Initial exposure to the microbial environment surrounding the infant can have a significant impact on gut microbiota development. External factors, such 
as maternal health status, mode of delivery, gestational age, and feeding regime, can impact the colonization and flux of microorganisms during this critical period in 
life. Subsequently, multiple studies have begun to focus on how these factors can affect the gut microbiome in early life. Moreover, in order to improve the health 
status of the infant gut, current focus is on the effect of probiotics and prebiotics in terms of their potential multifaceted health benefits. The current mini-review 
outlines a number of studies where either pro- or pre-biotics were utilized as a microbial therapeutic to improve infant health.
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of the gut microbiome, with recent studies focusing on similar 
microbial patterns between monozygotic twin pairs and their 
fraternal siblings (3, 4). Indeed, the duration of breast feeding 
and introduction of formula feed can play a significant role in 
shaping the gut microbiome (5–7). Thus, it is imperative that we 
understand how the introduction of particular microbial species 
and prebiotic additives may restore balance and ameliorate the 
effects associated with gastrointestinal (GI) disorders.
gi Microbial Development at Birth
Many studies have begun to focus on the development of the 
infant gut microbiome over time (8–10). A study by our group 
found that in full-term (FT) cesarean delivered infants, an 
increased fecal abundance of Firmicutes and lower abundance 
of Actinobacteria was evident after the first week of life; how-
ever, the gut microbiota of preterm (PT) infants displayed a 
significantly greater abundance of Proteobacteria compared to 
the FT infant group. Interestingly, the gut microbiota profile of 
FT cesarean delivered infants resembled that of the vaginally 
delivered infants at 8 weeks of life (1). In terms of gestational age 
at birth, the PT infant gut has previously been characterized by 
delayed microbial colonization, with reduced levels of anaerobic 
taxa such as Bifidobacterium and Bacteroides (11, 12). Indeed, 
gut microbiota development in PT infants has been found to 
correlate with the infant’s postconceptual age (13). Moreover, 
Stewart et  al. (14) described the impact of delivery mode on 
the PT gut microbiome and found no significant change in 
microbial diversity during the first 100 days of life.
Maternal–infant Transmission
The acquisition of microbial strains may occur through multiple 
different pathways. For example, the administration of the pro-
biotic Lactobacillus rhamnosus GG in a small subset of pregnant 
woman (between 30 and 36 weeks gestational age) found that 
maternal–infant transmission was successful and identified the 
strain in the feces of the infant cohort 6 months after birth (15). 
Indeed, maternal–infant transmission of mothers’ lactobacilli 
predominantly occurs when the infant is delivered vaginally 
(16, 17). It is understood that the vaginal tract harbors these 
lactobacilli to reduce the pH of the intestinal milieu and prevent 
the growth of potentially pathogenic microorganisms in the 
infant gut.
Interestingly, a number of studies have begun to examine 
microbial communities present within breastmilk. Nine genera 
have previously been identified as part of the “core” breastmilk 
microbiome, including Streptococcus, Staphylococcus, Serratia, 
Pseudomonas, Corynebacteria, Ralstonia, Propionibacterium, 
Sphingomonas, and Bradyrhizobiaceae (18). Several other studies 
3Watkins et al. Microbial Therapeutics for Gut Health
Frontiers in Nutrition | www.frontiersin.org October 2017 | Volume 4 | Article 48
have also identified the horizontal transfer of Lactobacillus, 
Staphylococcus, Enterococcus, and Bifidobacterium spp., from 
breastmilk to the infant gut (19–21). In a more recent study, 
Murphy et al. (22) reported the presence of 12 dominant gen-
era in the breastmilk of lactating mothers. Results from this 
study described a number of frequently shared taxa, including 
Bifidobacterium, Lactobacillus, Staphylococcus, and Enterococcus, 
common in both breastmilk and infant feces during the first 
3 months of life. Moreover, culture-dependent analysis identi-
fied Bifidobacterium breve and Lactobacillus plantarum present 
in both breastmilk and infant feces. Indeed, similar studies 
have also identified genomic patterns of Bifidobacterium and 
Lactobacillus spp. present in breastmilk and corresponding 
infant feces (23–25).
Recent studies have also begun to focus on microbial colo-
nization which may occur in utero. Isolation of microorganisms 
from the umbilical cord blood of cesarean delivered infants (26), 
as well as the detection of bacteria in “first-pass” meconium 
(27, 28), suggest that the fetus may be colonized at a low abun-
dance prior to exiting the womb. Moreover, research focused 
on the placental microbiome has found significant correlations 
between the placental and oral microbial communities (29). 
However, supporting evidence for the existence of a distinct 
placental microbiome is currently lacking (30). Thus, microbial 
colonization of the infant gut may be strongly influenced by the 
maternal microbiome, originating from several different niches, 
including the vaginal tract, breastmilk, and possibly the placenta.
Throughout the remainder of this mini-review, a number of 
studies will be discussed regarding prebiotic and probiotic treat-
ments to prevent and/or treat conditions linked to GI health in 
early life.
PReBiOTiCS
Human Milk Oligosaccharides (HMOs)
The current definition of prebiotics defined by Gibson et al. (31) 
describes “selectively fermented ingredients that result in specific 
changes, in the composition and/or activity of the GI microbiota, 
thus conferring benefit(s) upon host health.”
Human breastmilk is a natural prebiotic source which contains 
essential nutrients and growth factors required for development 
of a healthy gut microbiome. Selective proliferation of healthy 
intestinal bacteria is thought to be just one of the multiple benefits 
of exclusive breast feeding, in addition to the nutrient supply of 
HMOs and glycoconjugates it provides (32). As HMOs are not 
digested by the infant themselves, they reach the colon intact 
and act as an essential substrate for the growth of beneficial 
Bifidobacterium and Bacteroides spp. Breastfed infants have also 
been found to harbor gut microbial taxa with genes involved in 
the phosphotransferase system for carbohydrate uptake, in addi-
tion to harboring an increased abundance of microbial species 
commonly used as probiotics, such as L. johnsonii/L. gasseri, 
L. paracasei/L. casei, and B. longum (33). Moreover, Hill et al. (1) 
found that prolonged breast feeding (>4 months) had a signifi-
cant effect on the microbial composition of cesarean delivered FT 
infants at 24 weeks of life, in comparison to vaginally delivered 
infants, suggesting that breastmilk may prove to be even more 
beneficial in caesarian delivered infants.
Prebiotics and weaning
It is well known that the infant gut microbiome does not fully 
develop until an infant reaches 2–3 years of age. Therefore, it is 
important that we recognize the changes occurring in the infant 
gut during this transition from early infant feeding to solid foods. 
Indeed, the World Health Organisation (34) states that the appro-
priate age for complementary feeding is “6 to 23 months of age”; 
however, this can change in exceptionally difficult circumstances 
[e.g., very low birth weight (VLBW) infants]. The following stud-
ies investigate the role of diet and the introduction of galacto- 
and fructo-oligosaccharides (GOS and FOS) for improving gut 
microbiota development in early life.
In terms of diet, a recent study investigated the impact 
of different foods on the gut microbiota profile of a Danish 
infant cohort. Results from this study found strong correla-
tions between microbial taxa present and the dietary intake of 
foods high in protein and fiber; specifically meats, cheeses, and 
Danish rye bread (35). Interestingly, breastmilk/early infant 
feeding was correlated with the presence of Bifidobacteriaceae, 
Enterococcaceae, and Lactobacillaceae, whereas Lachnospiriaceae 
abundance was positively correlated with protein intake 
and negatively correlated with Bifidobacteriaceae. Moreover, 
Pasteurellaceae abundance was positively correlated with fiber 
and health conscious food choices (high in vegetable fats, fruits 
or fish, but low in sugar). Findings from this study suggest that 
the transition from breast feeding to “family-like” foods rich in 
fiber and protein significantly affects development of the infant 
gut microbiome (35). Digestion of these foods provides a vari-
ety of fermentable substrates necessary for the growth of colonic 
bacteria and thus further investigation into the by-products of 
predigested foods may provide valuable information to posi-
tively modulate the infant gut throughout weaning.
With respect to prebiotic supplementation of infant formulae, 
recent studies have investigated the use of GOS and FOS to 
reduce pH and produce a similar short-chain fatty acid (SCFA) 
profile to that of exclusively breastfed infants (36). Indeed, 
where infant formulae have been supplemented with GOS/FOS, 
a higher abundance of B. longum was found in the infant gut 
(37, 38). In addition, Haarman and Knol (38) found that infants 
consuming a standard formula (without prebiotic supplement) 
possessed a higher abundance of Bifidobacterium catenulatum 
and Bifidobacterium adolescentis, resembling a more adult-like 
microbiota. Alternatively, prebiotic inulin-type fructans and FOS 
can be found readily available in foods such as cereals, chicory, 
and bananas, which are recommended for infants during wean-
ing. These previously mentioned studies, and others (Table 1), 
provide evidence for the beneficial use of prebiotics, GOS, and 
FOS, to help maintain a well-balanced microbial progression 
from infancy to early adulthood.
Although synbiotics, a combination of both a probiotic and 
a prebiotic (51), were not discussed in this review, the beneficial 
effects of bovine milk oligosaccharides and Bifidobacterium spp. 
on the infant gut have been noted in two human interventions 
(Table 1).
TaBle 1 | (A) Prebiotics effective in altering the intestinal microbiota in human infant studies, (B) probiotic strains effective in altering the intestinal microbiota in a number 
of human infant studies, and (C) synbiotics effective in altering the intestinal microbiota in a number of human infant studies.
(a) infant study Prebiotic Duration Microbial shift Outcome Reference
Healthy PT–FF FOS 2 weeks ↑ Bifidobacterium
Bacteroides
↓ E. coli
Improved stool frequency (39)
Healthy FT–FF GOS + FOS 4–5 weeks ↓ Clostridia Improved stool frequency (40)
Healthy PT + FT–FF GOS + FOS 24 weeks ↕ Bifidobacterium
Clostridium
Increase in sIgA (41)
Healthy FT–FF GOS, beta-palmitate + acidified milk 135 days ↕ Bifidobacterium
Clostridium
Adequate growth. Increasing  
anthropometric parameters
(42)
Healthy FT–FF GOS + FOS 6 weeks ↑ Bifidobacterium Increase in acetate, butyrate,  
propionate. Reduced fecal pH
(43)
Healthy FT (>1 year age)–FF GOS, FOS + inulin 8 weeks ↕ Bifidobacterium
Clostridium perfringens
Increase in total organic acids.  
Lactacte, acetate, proprionate,  
butyrate
(44)
(B) infant study Probiotic Duration Microbial shift Outcome Reference
Healthy FT–FF L. rhamnosus GG 24 weeks ↑ Lactobacilli Increased length and weight.  
Improved growth
(45)
Low birth weight PT–BF + FF Bifidobacterium
breve, Bifidobacterium
longum ssp.
infantis,
B. longum ssp.
longum
6 weeks ↑ Bifidobacterium
↓ Clostridium
Enterobacteriaceae
Promoted the formation of a healthy  
gut microbiota. B. breve suggested  
more suitable for PT infants
(46)
Late PT infants–FF Clostridium butyricum, Bifidobacterium 1 week Not reported Proliferation of T lymphocytes.
Clinical evaluation for C. butyricum
(47)
Healthy FT–FF Bifidobacterium animalis ssp.lactis, 
Streptococcus thermophiles.
~1 year Not reported Lower frequency of reported colic  
or irritability.
Lower frequency of antibiotic use
(48)
(C) infant study Synbiotic Duration Microbial shift Outcome Reference
 Healthy FT–FF B. animalis ssp. lactis + bovine milk 
oligosaccharide
48 weeks ↑ Bifidobacterium
Lactobacillus
↓ Clostridium
Staphylococcus
Supports normal growth. Fecal IgA  
and pH similar to breastfed infant
(49)
 Healthy FT–FF B. animalis ssp. lactis + bovine milk 
oligosaccharide
24 weeks ↑ Bifidobacterium No differences in anthropometric  
measurements. Lower fecal pH
(50)
↑, increased levels; ↓, decreased levels; FF, formula fed; BF, breastfed; CS, cesarean section; VD, vaginally delivered; PT, preterm; FT, full term; GOS, galacto-oligosaccharides; FOS, 
fructo-oligosaccharides.
4
Watkins et al. Microbial Therapeutics for Gut Health
Frontiers in Nutrition | www.frontiersin.org October 2017 | Volume 4 | Article 48
PROBiOTiC inTeRvenTiOn
Health Benefits of Probiotics
Probiotics, described as “live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the 
host” (52–55), have been investigated as potential prophylactics 
and/or treatments to re-establish gut homeostasis (Table  1). 
Moreover, the metabolism of indigestible oligosaccharides and 
plant polysaccharides by probiotic microorganisms, such as 
Bifidobacterium spp., contributes to the production of microbial 
bioactive molecules, such as SCFAs (56).
Subsequently, probiotic treatment is being extensively 
studied in different conditions associated with a disturbance 
in the gut. Necrotizing enterocolitis (NEC), childhood obesity 
and autism will be discussed next to highlight the link between 
a microbial disturbance in the gut and the beneficial use of 
probiotic prophylaxis in early life. The following conditions 
have been chosen due to their significant prevalence in current 
literature.
necrotizing enterocolitis
Necrotizing enterocolitis, where portions of the bowel undergo 
necrosis, is the second most common cause of mortality in 
PT infants. Subsequent studies focused on improving health 
outcomes have found an increased abundance of Proteobacteria 
prior to and throughout the condition, including potentially 
pathogenic organisms such as Salmonella and Escherichia coli  
(57, 58). In a longitudinal study examining gut microbiota develop-
ment in PT twins, a twin pair discordant for NEC was discovered. 
Results from this study found clear changes attributable to anti-
biotic exposure and NEC development, with reduced microbial 
diversity and an increase in Escherichia spp. preceding NEC (59).
Probiotic prophylaxis has thus been investigated to examine 
whether this form of treatment could improve the quality of 
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life in PT infants. In a comprehensive review by AlFaleh and 
Anabrees (60), it was found that enteral administration of 
probiotics reduced incidence of severe NEC, and NEC-related 
mortality, with the majority of infants being administered a 
combination of Lactobacillus, Bifidobacterium, and Streptococcus 
spp. via breastmilk. Interestingly, the administration of bovine 
lactoferrin, in combination with L. rhamnosus GG, was found 
effective in reducing incidences of NEC in VLBW infants (61). 
In addition, the routine use of Lactobacillus reuteri DSM 17938 
(BioGaia®) was found to be highly successful in reducing rates 
of NEC in infants at highest risk (birth weights ≤ 1,000 g) (62).
Metabolic Syndrome (MS) and Obesity  
in Childhood
Metabolic syndrome, described by WHO in 1998, relates to any 
case of insulin resistance found in the presence of at least two of 
the following risk factors; hypertension, obesity, high triglyceride 
levels, or reduced high-density lipoprotein cholesterol levels. To 
examine the effectiveness of probiotics in preliminary animal tri-
als against MS, L. paracasei, L. rhamnosus, and Bifidobacterium 
animalis subsp. lactis were found to improve glucose–insulin 
levels and hepatic steatosis in a high-fat diet (HFD)-induced 
murine model (63). However, in a systemic review on the use of 
early probiotic intervention in human clinical trials, inadequate 
evidence was found to support the use of the probiotic L. rhamno-
sus GG or L. paracasei F19, when administered to both mothers 
and infants, in the prevention of childhood MS (64).
To tackle the prevalence of childhood obesity, scientists have 
begun to unravel the link between diet, the gut microbiome and 
consequent energy intake and adiposity. Turnbaugh et  al. (65) 
examined the hypothesis that particular communities of micro-
organisms could be involved directly with obesity in an obese 
mouse model. Results from the study found an increased capacity 
to harvest energy from diet, with an increased ratio of Firmicutes 
to Bacteroidetes (65). Further metagenomic analysis revealed 
that the microbiome of mice fed a high-fat/high-sugar (Western) 
diet, was significantly enriched in Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways involved in the fermentation 
of simple sugars (66). Thus, with the aim of reducing HFD-
induced weight gain in humans, animal studies are examining 
the antiobesity effects of different probiotics (67, 68). In-depth 
analysis of these animal studies may provide opportunities for the 
introduction of probiotics to help reduce weight gain in early life.
autism
The cause for autism spectrum disorder (ASD), a syndrome 
characterized by a deficit in social and communicative inter-
actions, is yet unclear; however, recent studies have revealed 
a link between symptomatic cognitive dysfunctions and GI 
distress through a connection in the central nervous system, 
coining the term “brain–gut axis.” There is now evidence that 
probiotics alleviate GI distress in various murine models 
which mimic the symptomatic traits of ASD (69, 70). Studies 
have found that a member of the Bacteroides spp., Bacteroides 
fragilis, acts as a natural anti-inflammatory, capable of inhibit-
ing inflammatory responses in a chemically induced murine 
model of experimental colitis (71, 72). Moreover, a maternal 
immune activation (MIA) model, which challenges the immune 
system and promotes inflammatory factors in pregnant dams, 
induces key features of ASD and thus serves as an appropriate 
murine model in testing B. fragilis as a potential therapeutic 
(70). Hsiao et al. (70) demonstrated the ability of B. fragilis to 
correct the levels of a MIA-induced serum metabolite which was 
found at significantly higher concentrations in MIA-offspring. 
Overall, B.fragilis improved gut permeability, as well as correct-
ing ASD-related behavioral abnormalities. This suggests that 
a microbe-mediated therapy, such as B. fragilis, may alleviate 
various behavioral disorders during childhood.
COnClUSiOn
Throughout this mini-review, we have discussed the introduction 
of microbial therapeutics, in addition to prebiotic supplementa-
tion, to highlight the health benefits for their use in relieving GI 
distress in early life.
With regards to infant formulae, prebiotic supplementation 
with a mixture of GOS/FOS can help mimic the composition of 
breastmilk and promote the development of Bifidobacterium in 
the infant gut, in particular B. longum.
In terms of the clinical use of probiotics, it is crucial that 
we develop standardized treatments which take into account 
the age group of a specific human cohort, in addition to health 
status of the group in question. In this respect, the appropri-
ate dose of a probiotic must be determined. Moreover, it is 
vital that we re-evaluate the safety of alternative probiotics, 
coined “next-generation probiotics” (NGPs). A preliminary 
evaluation on the safe use of a Bacteroides xylanisolvens isolate 
has recently been reported (73), in addition to the beneficial 
effects of Faecalibacterium prausnitzii (74, 75), and bacterial 
strains belonging to the Eggerthellaceae family, which produce 
metabolites with anti-inflammatory and cardioprotective prop-
erties (76). However, guidelines outlined by the European Food 
Safety Authority, and the Food and Agriculture Organization 
of the United Nations, have made it difficult to introduce these 
bacteria as food supplements. In terms of economic potential, 
further research is required to upscale these NGPs for food and/
or pharmaceutical industries. The industrial challenges may be 
overcome through high throughput selection of bacterial strains 
with the capacity to grow well in selective media and tolerate the 
presence of oxygen. In other words, the technological robustness 
of the strain in question must be tested, in addition to the suit-
able anaerobic media and encapsulation methods required to 
retain probiotic viability under good manufacturing practices. 
Moreover, in  silico screening of bacterial genomes will ensure 
the safety of these strains through the detection of antibiotic 
resistance and virulence genes. Alternatively, live biotherapeutic 
products (LBPs) may create an opportunity to introduce NGPs 
to the market (77). An LBP has recently been described as “a 
biological product that: (1) contains live organisms, such as 
bacteria; (2) is applicable to the prevention, treatment, or cure of 
a disease or condition of human beings; and (3) is not a vaccine” 
(78). In addition, O’Toole et al. (77) described future testing of 
LBPs as biological medicinal products, thereby providing new 
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opportunities to introduce NGPs as well characterized drugs to 
the market.
Overall, we conclude that additional studies are necessary 
to investigate the influence of prebiotics and probiotics in early 
life. It is important that we consider the mixed microbial com-
munities present within foods and select those which will survive 
and adapt readily in an industrial environment (79, 80). More 
importantly, we suggest if new probiotics and prebiotics are to be 
considered health beneficial in the European market, the neces-
sity for comprehensive, randomized controlled trials is vital. The 
current approach requires further strategy to provide consumers 
with valid information toward the use of probiotic and prebiotic 
supplementation in early childhood.
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